Prospective NASH market flips to over crowded as Big Pharma GLP-1s cast shadow over biotech breakthroughs

And just like that, we have a crowded race to be the first approved nonalcoholic steatohepatitis (NASH) treatment—a market that could grow to $108.4 billion globally by 2030.